Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αM.CAR4 T cells
- Development stage
- Preclinical
- Lead developer
- Mahidol University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
αM.CAR4 T cells (also known as anti-MUC1-CAR4 T cells) are fourth-generation chimeric antigen receptor (CAR) T cells designed to target Mucin 1 (MUC1), a transmembrane glycoprotein overexpressed in various solid tumors, including breast cancer and cholangiocarcinoma. Developed by researchers at Mahidol University, these CAR-T cells feature a fourth-generation CAR construct containing an anti-MUC1 single-chain variable fragment (scFv) linked to three costimulatory domains (CD28, CD137, and CD27) and the CD3ζ signaling domain. In preclinical studies, αM.CAR4 T cells demonstrated specific cytolytic activity against MUC1-positive tumor cells, enhanced proliferation, and reduced expression of the exhaustion marker PD-1 compared to earlier-generation CAR-T cells.
- Other names
- anti-MUC1-CAR4 T cellsanti-MUC-1-CAR4 T cellsanti-MUC 1-CAR4 T cellsfourth-generation anti-MUC1 CAR T cells
02
Targets
TNFRSF9 (CD137 extracellular domain)CD27 (Cluster of Differentiation 27)CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)MUC1 (Mucin-1 Antigen)
Beyond the preview
Go deeper on αM.CAR4 T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αM.CAR4 T cells.